A Phase I, Single-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Oral Doses of AZD2066 in Japanese Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2009
At a glance
- Drugs AZD 2066 (Primary)
- Indications Diabetic neuropathies; Gastro-oesophageal reflux; Neuropathic pain
- Focus Adverse reactions
- Sponsors AstraZeneca
- 26 Aug 2009 Actual patient number (132) added as reported by ClinicalTrials.gov.
- 26 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2009 Planned number of patients changed from 40 to 60, additional lead trial investigator (Neijber A) identified as reported by ClinicalTrials.gov.